DKN-01 and tislelizumab plus chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial

被引：0
|
作者：
Klempner, S. J. [1 ]
Chao, J. [2 ]
Uronis, H. [3 ]
Sirard, C. [4 ]
Kagey, M. [5 ]
Baum, J. [5 ]
Song, J. [6 ]
Wang, J. [7 ]
Sonbol, M. B. [8 ]
Wainberg, Z. A. [9 ]
Ajani, J. A. [10 ]
机构：
[1] MGH Massachusetts Gen Hosp, Med Oncol Dept, Boston, MA USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA
[3] Duke Univ, Med, Duke Canc Ctr, Med Ctr, Durham, NC USA
[4] Leap Therapeut, Clin Dev, Cambridge, MA USA
[5] Leap Therapeut, Translat Med, Cambridge, MA USA
[6] BeiGene Ltd, Biostat, San Mateo, CA USA
[7] BeiGene Ltd, Clin Dev, Beijing, Peoples R China
[8] Mayo Clin, Internal Med Dept, Canc Ctr, Phoenix, AZ USA
[9] UCLA, Med Hematol & Oncol, David Geffen Sch Med, Los Angeles, CA USA
[10] Univ Texas MD Anderson Canc Ctr, GI Med Oncol, Houston, TX USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1213P
引用
收藏
页码：S1103 / S1104
页数：2
相关论文
共 50 条
  • [1] DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial
    Klempner, Samuel J.
    Chao, Joseph
    Uronis, Hope Elizabeth
    Sirard, Cynthia A.
    Kagey, Michael
    Baum, Jason
    Song, James
    Wang, Jin
    Kim, In-Ho
    Lee, Keun Wook
    Oh, Do-Youn
    Sonbol, Bassam Bassam
    Wainberg, Zev A.
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
    Klempner, S. J.
    Sirard, C.
    Chao, J.
    Chiu, V.
    Mahalingam, D.
    Uronis, H.
    Kagey, M.
    Baum, J.
    Dayyani, F.
    Song, J.
    Wang, J.
    Iqbal, S.
    Tejani, M.
    Sonbol, M. B.
    Scott, A. J.
    Wainberg, Z.
    Ajani, J. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1048 - S1049
  • [3] A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab plus chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA)
    Klempner, Samuel J.
    Sonbol, Bassam Bassam
    Wainberg, Zev A.
    Uronis, Hope Elizabeth
    Chiu, Vi Kien
    Scott, Aaron James
    Iqbal, Syma
    Tejani, Mohamedtaki Abdulaziz
    Stilian, Melissa C.
    Thoma, Mathis
    Kagey, Michael
    Baum, Jason
    Sirard, Cynthia A.
    Altura, Rachel A.
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish
    Klempner, Samuel J.
    Sonbol, Mohamad Bassam
    Wainberg, Zev A.
    Uronis, Hope Elizabeth
    Chiu, Vi K.
    Scott, Aaron James
    Iqbal, Syma
    Tejani, Mohamedtaki Abdulaziz
    Chung, Vincent
    Stilian, Melissa C.
    Thoma, Mathis
    Zhang, Ying
    Kagey, Michael H.
    Baum, Jason
    Sirard, Cynthia A.
    Altura, Rachel A.
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
  • [5] Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).
    Lee, Keun-Wook
    Moehler, Markus H.
    Cunningham, David
    Wainberg, Zev A.
    Uronis, Hope Elizabeth
    Oh, Do-Youn
    Kim, In-Ho
    Shim, Byoung Yong
    Sym, Sun Jin
    Altura, Rachel A.
    Stilian, Melissa C.
    Parker, Elizabeth C.
    Klempner, Samuel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS484 - TPS484
  • [6] DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
    Pelster, Meredith
    Strickler, John H.
    Sirard, Cynthia A.
    Baum, Jason
    Haas, Mike
    Devoe, Craig E.
    Bustamante, Liliana
    Bubis, Jeffrey Alan
    Womack, Mark Sanders
    Wainberg, Zev A.
    Chung, Ki Y.
    Raff, Joshua P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 104 - 104
  • [7] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
    Moehler, Markus H.
    Kato, Ken
    Arkenau, Hendrik-Tobias
    Oh, Do-Youn
    Tabernero, Josep
    Cruz-Correa, Marcia
    Wang, HongWei
    Xu, Hui
    Li, Jiang
    Yang, Silu
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
  • [8] HERIZON-GEA-01: Zanidatamab plus chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
    Tabernero, Josep
    Shen, Lin
    Elimova, Elena
    Ku, Geoffrey
    Liu, Tianshu
    Shitara, Kohei
    Lin, Xiao
    Boyken, Lisa
    Li, Huiyan
    Grim, Jonathan
    Ajani, Jaffer
    FUTURE ONCOLOGY, 2022, 18 (29) : 3255 - 3266
  • [9] DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival
    Klempner, Samuel J.
    Bendell, Johanna C.
    Villaflor, Victoria Meucci
    Tenner, Laura LaNiel
    Stein, Stacey
    Naik, Girish S.
    Sirard, Cynthia A.
    Kagey, Michael
    Chaney, Marya F.
    Strickler, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] Phase (Ph) II study of zanidatamab plus chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
    Ku, G.
    Elimova, E.
    Denlinger, C. S.
    Mehta, R.
    Lee, K-W.
    Iqbal, S.
    Kang, Y-K.
    Oh, D-Y.
    Rha, S. Y.
    Kim, Y. H.
    Seol, Y. M.
    Mwatha, T.
    Grim, J.
    Ajani, J. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1044 - S1045
12345